2017~2019年我院门诊药房心脑血管类理血剂中成药使用情况分析

Analysis on the use of cardio-cerebrovascular blood regulating agents in outpatient pharmacy of our hospital from 2017 to 2019

目的了解惠州市第一人民医院2017~2019年心脑血管类理血剂中成药(以下简称“理血剂”)的使用情况,为临床合理用药提供参考。方法从我院信息HIS系统抽取2017~2019年“理血剂”的相关数据,采用世界卫生组织推荐的限定日剂量(DDD)和药品金额,对“理血剂”的年销售金额、年增长率、用药频度(DDDs)、排序比(B/A)和限定日费用(DDC)等进行统计分析。结果2017~2019年,我院“理血剂”的年销售金额依次是343.49、389.83、428.23万元,分别占医院药品销售总金额的3.35%、3.51%、3.21%。2018年“理血剂”的年增长率为13.50%,2019年“理血剂”的年增长率为9.85%。单品种销售金额排序前3位的是麝香保心丸、心可舒片、脑栓通胶囊。DDDs排序中,血塞通胶囊、速效救心丸、银杏酮酯滴丸、脉血康肠溶片的用药频率有较大变动外,其余药品的用药频率基本稳定。DDC值基本保持稳定,近3年药品价格稳定。结论2017~2019年我院“理血剂”应用情况较为理想,但需对药品的不合理使用加强管理,做到“安全、有效、经济、合理”。

Objective To understand the use of cardio-cerebrovascular blood-regulating agents(hereinafter referred to as"blood-regulating agents")in Huizhou First People′s Hospital from 2017 to 2019,so as to provide reference for clinical rational drug use.Methods The relevant data of"blood-regulating agents"from 2017 to 2019 were extracted from the information HIS system of our hospital,and the defined daily dose(DDD)and drug sum recommended by World Health Organization were used to analyze the annual sales,annual growth rate,medication frequency(DDDs),ranking ratio(B/A)and defined daily cost(DDC)of"blood-regulating agents".Results From 2017 to 2019,the annual sales for"blood regulating agents"in our hospital were 3.4349,3.8983 and 4.2823 million yuan respectively,accounting for 3.35%,3.51%and 3.21%of the total amount of drugs in the hospital,respectively,compared with 2017 and 2018.The growth rates were 13.5%and 9.85%respectively.The annual growth rate of"blood management agents"was 13.50%in 2018 and 9.85%in 2019.The top three sales amount of single variety were Shexiang Baoxin Pills,Xinkeshu Tablets and Naosuantong Capsules.In the order of DDDs,the medication frequency of Xuesaitong Capsules,Quick-acting Heart-saving Pills,Ginkgo Ketone Ester Dropping Pills and Maixuekang Enteric-coated Tablets changed greatly,but the frequency of other drugs was basically stable.The DDC value remained basically stable,and drug prices were stable in the past three years.Conclusion The application of"blood-regulating agent"in our hospital from 2017 to 2019 is ideal,but it is still necessary to strengthen the management of the unreasonable use of drugs to be"safe,effective,economical and reasonable".